Drugs and Diagnostics for Hematological Disorders: Global Markets

PUBLISHED: July 2, 2024

PAGES: 133 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

The North American market for drugs and diagnostics for hematological disorders is expected to grow from $58.9 billion in 2024 and is projected to reach $85.7 billion by the end of 2029, at a CAGR of 7.8% during the forecast period of 2024 to 2029.

The European market for drugs and diagnostics for hematological disorders is expected to grow from $34.1 billion in 2024 and is projected to reach $47.8 billion by the end of 2029, at a CAGR of 7.0% during the forecast period of 2024 to 2029.

Report Scope

This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.

The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.

The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.

Report Includes

49 data tables and 44 additional tables
An overview of the current and future global markets for drugs and diagnostics for hematological disorders
Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
Review of technological developments, product introductions, and other recent industry activity of the major players
Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
An analysis of recent patents
A look at the competitive landscape, including companies' market shares, M&A activity and venture funding
Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Product Code: PHM116C

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
PESTEL Analysis
Political
Economic
Social
Technological
Environmental
Legal
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Threat of Substitutes
Competition in the Industry
Supply Chain and Logistics for Hematological Instruments

Chapter 3 Market Dynamics

Market Drivers
Incidence of Blood Disorders
Rising Use of Automation
Diagnosis of Hematology Disorders
Increasing Government and Private Funding for Treatment
Market Restraints
High Cost of Instruments
High Cost of Treatment
Reimbursement Challenges for Physicians
Market Opportunities
Rising Health Awareness
Emerging Economies

Chapter 4 Patent Landscape and Current Developments in Drugs

Patent Landscape
New Approvals

Chapter 5 Emerging Technologies and Developments

Overview
Emerging Technologies
AI-Assisted Diagnosis
Next-Generation Sequencing (NGS)
Microfluidics and Lab-on-a-Chip Devices
Gene Therapies
Immunotherapies
Clinical Trials

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Segmentation by Market
Hematological Disorders Diagnostics Market
Hematological Disorders Diagnostic Market, By Product Type
Hematological Disorders Diagnostic Market, By End User
Hematology Drug Market
Hematology Drug Market, By Drug Type
Geographic Breakdown
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Leading Companies
Hematological Disorder Diagnostics
Hematological Disorder Drugs
New Developers of Drugs for Rare Hematology Disorders

Chapter 8 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBOTT
AMGEN INC.
BIO-RAD LABORATORIES INC.
BRISTOL MYERS SQUIBB CO.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
NOVARTIS AG
SANOFI
SYSMEX CORP.
TAKEDA PHARMACEUTICAL CO. LTD.

Product Code: PHM116C

List of Tables

Summary Table : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 1 : Blood-Related Disorders
Table 2 : Incidence of Blood Cancer Types in U.S., 2023
Table 3 : Total Cost of Care for CLL Patients Treated in the U.S., 2023
Table 4 : Hematology Drugs and their Patent Expiration Dates, 2024
Table 5 : Approved Hematology Drugs, 2023
Table 6 : Clinical Trial Studies on Leukemia, March 2024
Table 7 : Clinical Trial Studies on Lymphoma, March 2024
Table 8 : Clinical Trial Studies on Bleeding Disorders, March 2024
Table 9 : Clinical Trial Studies on Myelofibrosis, March 2024
Table 10 : Clinical Trial Studies on Anemia, March 2024
Table 11 : Clinical Trial Studies on Multiple Myeloma, March 2024
Table 12 : Clinical Trial Studies on Thalassemia, March 2024
Table 13 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 14 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
Table 15 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 16 : Global Market for Hematology Instruments and Software, by Region, Through 2029
Table 17 : Global Market for Hematology Reagents, by Region, Through 2029
Table 18 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 19 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
Table 20 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
Table 21 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
Table 22 : Global Market for Hematology Drugs, by Region, Through 2029
Table 23 : Global Market for Hematology Drugs, by Drug Type, Through 2029
Table 24 : Drugs Approved for Hematologic Cancers
Table 25 : Global Market for Hematology Oncology Drugs, by Region, Through 2029
Table 26 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
Table 27 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 28 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 29 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 30 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 31 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 32 : North American Market for Hematology Drugs, by Drug Type, Through 2029
Table 33 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 34 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 35 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 36 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 37 : European Market for Hematology Drugs, by Drug Type, Through 2029
Table 38 : Incidence of Blood-Related Cancers, by Country, 2022
Table 39 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 40 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 41 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 42 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 43 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
Table 44 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
Table 45 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 46 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 47 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 48 : RoW Market for Hematology Drugs, by Drug Type, Through 2029
Table 49 : Revenue Generated by Drugs for Hematology Disorders, 2023
Table 50 : New Developers of Drugs for Hematology Disorders
Table 51 : Report Sources
Table 52 : Abbreviations Used in This Report
Table 53 : Abbott: Company Snapshot
Table 54 : Abbott: Financial Performance, F.Y. 2022 and 2023
Table 55 : Abbott: Product Portfolio
Table 56 : Abbott: News/Key Developments, 2023
Table 57 : Amgen Inc.: Company Snapshot
Table 58 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 59 : Amgen Inc.: Product Portfolio
Table 60 : Amgen Inc.: News/Key Developments, 2021-2024
Table 61 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 62 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 64 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023
Table 65 : Bristol Myers Squibb Co.: Company Snapshot
Table 66 : Bristol Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 67 : Bristol Myers Squibb Co.: Product Portfolio
Table 68 : Bristol Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 69 : Danaher Corp.: Company Snapshot
Table 70 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 71 : Danaher Corp.: Product Portfolio
Table 72 : Danaher Corp.: News/Key Developments, 2022-2024
Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 75 : F. Hoffmann-La Roche Ltd: Product Portfolio
Table 76 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 77 : Novartis AG: Company Snapshot
Table 78 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 79 : Novartis AG: Product Portfolio
Table 80 : Novartis AG: News/Key Developments, 2022
Table 81 : Sanofi: Company Snapshot
Table 82 : Sanofi: Financial Performance, FY 2022 and 2023
Table 83 : Sanofi: Product Portfolio
Table 84 : Sanofi: News/Key Developments, 2023
Table 85 : Sysmex Corp.: Company Snapshot
Table 86 : Sysmex Corp.: Financial Performance, FY 2022 and 2023
Table 87 : Sysmex Corp.: Product Portfolio
Table 88 : Sysmex Corp.: News/Key Developments, 2021-2023
Table 89 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 90 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022
Table 91 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 92 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023

List of Figures

Summary Figure : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
Figure 1 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders
Figure 2 : Incidence of Blood Cancer Types, by Region, 2022
Figure 3 : Clinical Trial Phases of Drugs for Various Blood-Related Disorders, March 2024
Figure 4 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
Figure 5 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
Figure 6 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
Figure 7 : Global Market Shares of Hematology Drugs, by Drug Type, 2023
Figure 8 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 9 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
Figure 10 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 11 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 12 : Abbott: Revenue Shares, by Business Unit, F.Y. 2023
Figure 13 : Abbott: Revenue Shares, by Country/Region, FY 2023
Figure 14 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 15 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 16 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 17 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 18 : Bristol Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 19 : Bristol Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 20 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 21 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 24 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 25 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 26 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 27 : Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 28 : Sysmex Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 29 : Sysmex Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 30 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022